Sam Fazeli

And, you know, as you talk about luck, I don't think any scientist would put luck aside ever as a major factor in their own success, in the success of their science.

And even companies, you know, I've just finished reading a completely unrelated autobiography of Bill Gates.

And when we are together for dinner, I could talk to you about the one event that I think happened, which was luck that enabled.

I mean, it's my view.

So anyway, just before we move on to the broader topic of China, is there you obviously have done NewCo with ForBeyond recently announced in August.

I do want to talk to us a little bit about that, and then we move on to China.

What is it?

Should we expect more?

How does that all come together?

Great.

Now I'm going to move on to China quickly.

I wish we had more time.

There's so many interesting... So another drug that I was quite keen on, it was PD-1 targeted IL-2 fusion protein.

And it's funny, I just saw a paper published yesterday, or two days ago, October 13th,

From Kevin Barry's lab, IL-2 signaling induces NK cell production of FLT3LG, augmenting anti-PD-1 immunotherapy.

There's a lot of interest in these smart cytokines, etc.

But we don't have much time for that.

Maybe that's a reason for you to accept another invitation from me in the future.

We'll think about it.

But I want to talk about China Biotech.